Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease. Its approval was based on the treatment demonstrating what the FDA described as a “statistically significant reduction in clinical decline on the integrated Alzheimer's Disease Rating Scale (iADRS) compared to placebo”. Anne White, Eli Lilly’s executive vice president, said that the amyloid plaque-targeting therapy had shown “very meaningful results for people with early symptomatic Alzheimer's disease.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,